4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001714899-22-000131
Director sold 20,000 shares at an average $31.61 ($632,282)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Tessier-Lavigne Marc Director | 2022-08-23 | Sale | −19,900 | $31.61 | $629,039 | 1,930,456 | D: show line 1 in the form |
| Tessier-Lavigne Marc Director | 2022-08-23 | Sale | −100 | $32.43 | $3,243 | 1,930,356 | D: show line 2 in the form |
| Open-market sales · 20,000 sh · avg $31.61 · $632,282 | |||||||
Loading xslF345X03/wf-form4_166146545134466.xml…